CDCN Annual Working Dinner

The CDCN Annual Accelerating Research & Treatment for Castleman Disease Working Dinner at ASH

The Castleman Disease Collaborative Network (CDCN) will host the 14th Annual “Accelerating Research & Treatment for Castleman Disease,” working dinner in-person on December 6, 2025 from 7:30 to 9:00 pm EST at the annual American Society of Hematology Meeting in Orlando, FL. This year’s dinner will be held in the Hyatt Regency Orlando, Bayhill 21-22, located at 9801 International Drive, Orlando, FL 32819.

We are excited to bring together fellow physicians and researchers from around the globe, who are dedicated to advancing the understanding and treatment of Castleman disease. The in-person event will discuss cutting edge research and important issues for patient care.

Please RSVP for the working dinner here.

In addition to the working dinner, we will host a Dinner, Drinks and Data poster session to showcase research related to Castleman disease at the same location prior to the working dinner meeting. This meeting will take place from 6:30 to 7:25 pm EST. All are welcome.

This annual gathering is a tremendous example of the power of the CDCN’s collaborative research approach to defeating Castleman disease. For additional information, please reach out to Madison Ahearn at madison@cdcn.org.

2025 CDCN Working Dinner Posters

Submitted by
Abstract Title
Ciprian Tomuleasa Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience
Abstract Link, Poster Link
Katherine Forsyth, PhD Increased Type I Interferon Signaling is a Hallmark of Idiopathic Multicentric Castleman Disease
Abstract Link, Poster Link
Yusuke Ueda Cytokine and Chemokine Profiling in TAFRO Syndrome and Idiopathic Multicentric Castleman Disease
Abstract Link, Poster Link
Miao-yan Zhang Germline OSMR mutation drives familial unicentric Castleman disease with osteosclerosis
Abstract Link, Poster Link
Nicole Princic Retrospective real-world data analysis of morbidity burden and healthcare costs in idiopathic multicentric castleman disease compared with matched controls (BURDEN-iMCD)
Abstract Link, Poster Link
Kezhi Huang MEFV E148Q-P369S-R408Q Germ Line Variant Identified from the Adolescent iMCD-TAFRO Family Conferred Severe Disease Manifestations in a Cohort of 37 Patients with Castleman Disease
Abstract Link, Poster Link
Melanie Mumau, PhD T follicular helper cells are mis-localized in iMCD, a cytokine storm disorder
Poster Link
Bridget Austin, MS Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe and Responds to Siltuximab
Poster Link
Kayla McHugh Idiopathic Multicentric Castleman Disease Unresponsive to One IL-6 Inhibitor May Respond to Another IL-6 Inhibitor
Poster Link
Jian Chen Relationship between changes in quality of life and social function and treatment response in patients with idiopathic multicentric Castleman disease A single-center observational longitudinal survey
Poster Link
Siyuan Li Is “severe” idiopathic multicentric Castleman disease (iMCD)idiopathic plasmacytic lymphadenopathy (IPL) really severe?
Poster Link
Yu-han Gao PRKRA Associated with NF-κB Activation in Pulmonary Involvement of Idiopathic Multicentric Castleman Disease
Poster Link
Yu-han Gao Prognostic Significance of Pulmonary Involvement in Idiopathic Multicentric Castleman Disease
Poster Link
Lu Zhang, MD Idiopathic multicentric Castleman disease – TAFRO: a potentially curable disease
Poster Link
Michael Gonzalez, PhD Somatic mutation discovery in idiopathic multicentric Castleman disease (iMCD) lymph node tissue identifies dysregulated intracellular calcium signaling as a potential disease mechanism and therapeutic target
Poster Link
Joe Zinski, PhD VXGBoost Profiling of Quantitative Lymph-Node and Symptom Signatures Distinguishes Idiopathic Multicentric Castleman Disease and Its Clinical Subtypes
Poster Link
Kelly Makarounas-Kirchmann Treatment Burden In Patients with Idiopathic Multicentric Castleman Disease and its Impact On Daily Life: Results From An International Patient Survey
Poster Link
Larissa Borys Comparable Response Rates to Therapies in Idiopathic Multicentric Castleman Disease Patients With and Without Expert-Confirmed Diagnoses
Poster Link

 

This event is co-sponsored by the CDCN and Recordati.

Arrow Shape Facebook Instagram Twitter Youtube Play Arrow Left